English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/34709
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

How does pindolol improve antidepressant drug action?

AuthorsArtigas, Francesc ; Celada, Pau ; Laruelle, Marc; Adell, Albert
Issue DateMay-2001
PublisherElsevier
CitationTrends in Pharmacological Sciences 22 (5) : 224-228 (2001)
AbstractSince 1994, the β-adrenoceptor and 5-HT1A/1B receptor ligand pindolol has been used to accelerate or enhance the clinical effects of antidepressant drugs, such as the selective 5-HT reuptake inhibitors (SSRIs), that act primarily on 5-HT-containing neurones. Pindolol was initially thought to act by preventing the inhibition of 5-HT release, elicited by SSRIs and other 5-HT-acting drugs, as a result of its ability to antagonize the action of 5-HT at midbrain raphe 5-HT1A autoreceptors that control the activity of ascending 5-HT-mediated pathways. However, the partial agonist properties of pindolol at 5-HT1A receptors and β-adrenoceptors suggest that other explanations for its action are also possible. In this article, recent controversial data on the mechanism of action of pindolol, which are crucial for the development of more rapid and efficient antidepressant therapies, will be discussed.
Publisher version (URL)http://dx.doi.org/10.1016/S0165-6147(00)01682-5
URIhttp://hdl.handle.net/10261/34709
DOI10.1016/S0165-6147(00)01682-5
ISSN0165-6147
E-ISSN1873-3735
Appears in Collections:(IIBB) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.